The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase 3 study of oral lenalidomide as maintenance therapy for patients with B-cell chronic lymphocytic leukemia (CLL).
Asher Alban Akmal Chanan-Khan
No relevant relationships to disclose
Andrey Zaritskey
Honoraria - Novartis
Expert Testimony - Novartis
Miklos Egyed
No relevant relationships to disclose
Samuel Vokurka
Honoraria - Celgene
Olga Samoylova
No relevant relationships to disclose
Anna Schuh
Honoraria - Celgene; Gilead Sciences; GlaxoSmithKline; Roche
Research Funding - GlaxoSmithKline
David Simpson
No relevant relationships to disclose
Jay M. Mei
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Natalia Oliveira
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Oliver Kong
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Robin FoĆ 
Honoraria - Celgene
Expert Testimony - Celgene